Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS

被引：0
|
作者：
Sobecks, Ronald
Rybicki, Lisa [1 ]
Kalaycio, Matt
Dean, Robert
Andresen, Steven [1 ]
Pohlman, Brad
Bolwell, Brian J.
Copelan, Edward A.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1427 / 1428
页数：2
相关论文
共 50 条
  • [1] Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
    R M Sobecks
    L Rybicki
    M Yurch
    M Kalaycio
    R Dean
    S Andresen
    B Pohlman
    H Duong
    B Bolwell
    E Copelan
    Bone Marrow Transplantation, 2012, 47 : 633 - 638
  • [2] Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
    Sobecks, R. M.
    Rybicki, L.
    Yurch, M.
    Kalaycio, M.
    Dean, R.
    Andresen, S.
    Pohlman, B.
    Duong, H.
    Bolwell, B.
    Copelan, E.
    BONE MARROW TRANSPLANTATION, 2012, 47 (05) : 633 - 638
  • [3] Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Progenitor Cell Transplant Conditioning for Plasma Cell Myeloma
    Sobecks, Ronald
    Rybicki, Lisa
    Dean, Robert M.
    Abounader, Donna
    Andresen, S.
    Hien Duong
    Reu, Fred
    Bolwell, Brian
    Copelan, Ed
    Kalaycio, Matt E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S190 - S190
  • [4] Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning
    Kerbauy, Fabio R.
    Rodrigues, Morgani
    de Souza Santos, Fabio Pires
    Sobrinho, Jairo Nascimento
    Kutner, Jose Mauro
    Torres, Margareth A.
    Feitosa Ribeiro, Andreza Alice
    de Lima, Marcos
    Hamerschlak, Nelson
    LEUKEMIA & LYMPHOMA, 2011, 52 (02) : 321 - 324
  • [5] Is Busulfan and Fludarabine an Optimal Myeloablative Hematopoietic Stem Cell Transplant (HSCT) Conditioning Regimen in Children with AML/MDS ?
    Ramzan, Mohammed
    Ali, Muhammad
    Krueger, Joerg
    Alexander, Sarah
    Dupuis, Lee
    Finkelstein, Yaron
    Klein, Talia
    Sung, Lillian
    Frangoul, Haydar A.
    Schechter, Tal
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S350 - S350
  • [6] Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients
    Abbasi, Nissa
    Vadnais, Barbara
    Knutson, Jennifer A.
    Blough, David K.
    Kelly, Edward J.
    O'Donnell, Paul V.
    Deeg, H. Joachim
    Pawlikowski, Matthew A.
    Ho, Rodney J. -Y.
    McCune, Jeannine S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (10): : 1429 - 1438
  • [7] A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
    Andersson, Borje S.
    Thall, Peter
    Valdez, Benigno C.
    Ma, Junsheng
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin M.
    Bashir, Qaiser
    Ciurea, Stefan O.
    Gulbis, Alison
    Hosing, Chitra
    Jones, Roy B.
    Kawedia, Jitesh
    Kebriaei, Partow
    Kornblau, Steven M.
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth J.
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BLOOD, 2020, 136
  • [8] Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
    J De La Serna
    J Sanz
    A Bermúdez
    M Cabrero
    D Serrano
    C Vallejo
    V Gómez
    J M Moraleda
    S G Perez
    M D Caballero
    E Conde
    J J Lahuerta
    G Sanz
    Bone Marrow Transplantation, 2016, 51 : 961 - 966
  • [9] Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
    De La Serna, J.
    Sanz, J.
    Bermudez, A.
    Cabrero, M.
    Serrano, D.
    Vallejo, C.
    Gomez, V.
    Moraleda, J. M.
    Perez, S. G.
    Caballero, M. D.
    Conde, E.
    Lahuerta, J. J.
    Sanz, G.
    BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 961 - 966
  • [10] Phase II Trial of Reduced Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL
    Chen, Yi-Bin
    Li, Shuli
    Del Rio, Candice
    Coughlin, Erin
    Ballen, Karen K.
    Cutler, Corey S.
    Dey, Bimalangshu R.
    Ho, Vincent T.
    McAfee, Steven L.
    Spitzer, Thomas R.
    Alyea, Edwin P., III
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S217 - S218
12345